Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received a second indication approval...
Pfizer’s 25-Valent Pneumococcal Vaccine Candidate Shows Superior Serotype 3 Response in Phase II Infant Study
Pfizer Inc. (NYSE: PFE) announced positive readouts from a Phase II clinical study evaluating its...
Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio
Medtronic plc (NYSE: MDT) announced its intent to acquire SPR Therapeutics, Inc., a privately held...
BeOne Medicines Launches “One Save Changes Everything” Global Cancer Care Initiative, Partnering With Soccer Legend Tim Howard
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene, Ltd., today...
Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows
Bristol-Myers Squibb Company (BMS, NYSE: BMY) announced a strategic agreement with artificial intelligence pioneer Anthropic...
CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
CBC Group, the Singapore-based healthcare private equity firm, and Global Healthcare Opportunities (GHO), the UK-headquartered...
Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
Sanofi SA (NASDAQ: SNY) announced today positive data from the global ElevAATe Phase II clinical...
Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
A federal jury in the U.S. District Court for the District of Massachusetts returned a...
Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
Novartis AG (NYSE: NVS) announced today new data from the PSMAddition Phase III clinical trial...
China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week...
Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets
Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced today a strategic partnership agreement with two undisclosed...
Shanghai ZJ Bio-Tech Secures International Approvals for Molecular Diagnostic Platforms in Netherlands and Mexico
Shanghai ZJ Bio-Tech Co., Ltd. (SHA: 688317), a leading Chinese molecular diagnostic reagent specialist, announced...
Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial
Bayer AG (ETR: BAYN) announced today that the U.S. Food and Drug Administration (FDA) has...
UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis
UCB (EBR: UCB) announced today Week 16 data from the BE BOLD Phase III clinical...
United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization
United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from...
ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient...
Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri
Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and...
GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams
GlaxoSmithKline plc (GSK) (NYSE: GSK) has restructured its vaccine business operations in China, splitting the...
Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34%...